Company news

NeuroSense Therapeutics Ltd. news in 2023

NeuroSense Therapeutics Ltd.'s news releases, calls and decks from 2023, newest first.

View company

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

December 26, 2023

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

December 13, 2023

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

December 4, 2023

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

December 3, 2023

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

November 27, 2023

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

November 12, 2023

NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences

November 8, 2023

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

November 5, 2023

NeuroSense Therapeutics to Participate in BIO-Europe Fall

October 31, 2023

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC

October 18, 2023

NeuroSense CEO Provides Q3 2023 Update

October 16, 2023

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

October 3, 2023

NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results

October 1, 2023

European Medicines Agency Grants NeuroSense SME Status

September 19, 2023

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC

September 18, 2023

NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.

September 13, 2023

NeuroSense to Host Investor Webinar on September 12, 2023

September 5, 2023

NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

August 15, 2023

NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023

July 16, 2023

NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit

July 10, 2023

NeuroSense CEO Provides Q2 2023 Update

July 5, 2023

NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023

May 31, 2023

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

May 14, 2023

NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study

May 1, 2023

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment

April 16, 2023

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

March 26, 2023

NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference

March 22, 2023

NeuroSense Announces Year End 2022 Financial Results and Provides Business Update

March 21, 2023

NeuroSense Therapeutics to Participate in BIO-Europe Spring

March 15, 2023

NeuroSense Therapeutics Ltd. to participate in renmark's virtual Non-Deal roadshow series on, Tuesday, March 21 and Tuesday, March 28, 2023

March 13, 2023

NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts

February 12, 2023

NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

February 8, 2023

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

February 7, 2023

NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

February 5, 2023

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

January 18, 2023

Decks in 2023